The observations nobody wants to receive.

A huge beat, thinly covered

Regulatory decisions move billions around every week. An FDA warning letter can vaporize $2B in market cap before lunch (ask ImmunityBio, whose Chairman told a podcast his drug could "cure cancer" last month and got his answer on Monday). SEC settlements quietly close fraud cases while the market looks the other way. Pharma buys biotech to plug a patent cliff that most retail investors still treat as a rounding error.

The job demands maybe a dozen full-time newsrooms. Three exist. Four if you stretch the definition. Most of them sit behind $300/year paywalls. The journalism is genuinely good. The pricing targets pharma comms directors with an expense account, while the compliance officer three years in just wants to read the damn news.

So yeah, we built this instead.

What we cover

Four beats. FDA enforcement: warning letters, CRLs, AdComm decisions, any 483 findings we can actually pull via FOIA. SEC actions: enforcement cases, disclosure failures, insider trading, whistleblower payouts. Deals: pharma and biotech M&A, fundraising rounds, and the math behind why someone just paid 3x revenue. Legal: patent wars, DOJ prosecutions, qui tam settlements, trade policy fights.

We read the filings for you, then ask the one question worth asking on any given story: who cares, and why?

• Money. Who paid, how much, to whom, at what multiple. The dollar amount goes in the first paragraph. Always.
• Drama. Who got fired. Who's suing whom. Which CEO said the quiet part on a podcast and cost shareholders a few hundred million before the episode finished editing.
• Precedent. When one weird ruling or deal quietly rewrites how the next ten get done.

How we write

Short. We open on the fact. 200 words if the story is a 200-word story, 600 if it's a 600-word story, stopping the moment the point lands. We run on zero ads, so reading time is free of any incentive to inflate it.

We use direct verbs. If the FDA rejected something, the verb is "rejected," full stop. If a deal smells overpriced, we'll say so and show the math.

The business model

Free to read, funded out of pocket for now. Editorial stays independent from whatever sponsorship or partnership model we eventually pick.

The math works because we keep the newsroom small and hand the boring parts to machines: monitoring RSS feeds, flagging what's worth reading, drafting first passes. That frees up hours for the part a human has to handle anyway — the angle, the context, the "wait, that number doesn't add up" moment at 11pm.